Back to News
Market Impact: 0.15
Lōkahi Therapeutics™ Advances its Proprietary ai² PIPELINE (formerly ai² Futures Lab) Process from Internal Asset Engine to Revenue-Generating Platform
Source: Business Wire
Artificial IntelligenceTechnology & InnovationHealthcare & BiotechCompany Fundamentals
Lōkahi Therapeutics announced that its proprietary ai² PIPELINE process is advancing from an internal asset-development engine into a revenue-generating platform. The release signals a potential expansion of the company's business model through commercialization of its AI-enabled drug-development capabilities, though no financial metrics, customer contracts, or revenue targets were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- OpenAI’s agent hacked Australia’s Medicare website—the latest rogue AI incident that the company didn’t know about for months
- Chinese authorities reportedly in possession of F-35 components in Hong Kong
- Meta announces new lightweight virtual reality glasses to one-up Apple’s Vision Pro
- How Meta took the lead in the race for the post-smartphone world
- Markets are rapidly coming around to the reality that the Fed has a lot more work to do
- SoftBank shares jump over 7% after $11.1 billion bond issuance to fund OpenAI bet